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tolerance through the generation of regulatory 
T cells in rats
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Abstract 
Background: The transcription factor forkhead box P3 (Foxp3) is a master regulatory gene necessary for the develop-
ment and function of CD4+CD25+ regulatory T cells (Tregs). Mesenchymal stem cells (MSC) have recently emerged 
as promising candidates for cell-based immunosuppression/tolerance induction protocols. Thus, we hypothesized 
that MSC-based Foxp3 gene therapy would improve immunosuppressive capacity of MSC and induce donor-specific 
allograft tolerance in rat’s liver allograft model.
Methods: The present study utilized a lentivirus vector to overexpress the therapeutic gene Foxp3 on MSC. In vivo, 
Injections of 2 × 106 MSC, FUGW-MSC or Foxp3-MSC into the portal vein were carried out immediately after liver 
transplantation.
Results: Successful gene transfer of Foxp3 in MSC was achieved by lentivirus carrying Foxp3 and Foxp3-MSC engraft-
ment in liver allograft was confirmed by fluorescence microscopy. Foxp3-MSC treatment significantly inhibited the 
proliferation of allogeneic ACI CD4+ T cells to splenocytes (SC) from the same donor strain or third-party BN rat 
compared with MSC. Foxp3-MSC suppressive effect on the proliferation of CD4+ T cells is contact dependent and 
associated with Programmed death ligand 1(PD-L1) upregulation in MSC. Co-culture of CD4+ T cells with Foxp3-MSC 
results in a shift towards a Tregs phenotype. More importantly, Foxp3-MSC monotherapy achieved donor-specific liver 
allograft tolerance and generated a state of CD4+CD25+Foxp3+ Tregs-dependent tolerance.
Conclusion: Foxp3-engineered MSC therapy seems to be a promising and attractive cell therapy approach for induc-
ing immunosuppression or transplant tolerance.
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Background
Transplant tolerance describes immunological unrespon-
siveness to donor alloantigens without the need for long-
term administration of immunosuppressive drugs, while 
immune responsiveness to pathogens and malignant cells 
is maintained [1]. It is a major goal in transplantation. 
Gene therapy, in which malfunctioning cells are repaired 
by mending their DNA, offers an elegant solution to 
induce transplant tolerance. However, many potential 
problems associated with this modality of treatment 
have been encountered, including difficulty in regulating 
transgene expression, safety concerns about malignancy, 
infection, and inflammation [2, 3]. Determining a safe 
and efficient means of gene delivery and finding an opti-
mal gene for such are believed to be keys to solving these 
problems.
Mesenchymal stem cells (MSC) are considered as adult 
stem cells with the greatest therapeutic potential because 
of their characteristics, which include plasticity, migra-
tory ability, paracrine activity, and immunosuppressive 
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activity [4, 5]. This potential may be amplified by trans-
forming them with genes that will improve their thera-
peutic ability [4, 6]. MSC have recently emerged as 
promising candidates for cell-based immunotherapy 
[7–9]. MSC can inhibit immune responses and influence 
all components of the immune system as shown for T-, 
B-, natural killer-, monocytic and dendritic cells in vitro 
and in vivo [5, 10]. With regard to solid organ transplan-
tation, MSC were reported to prolong skin allograft sur-
vival in baboons [11], heart [7, 8], liver [9], renal [12] and 
islet [13] graft survival in rodent transplantation models. 
In addition, MSC were already successfully employed in 
several clinical trials [14, 15] most notably to ameliorate 
steroid-resistant graft-versus-host disease in a phase II 
study [16]. Importantly, the immunoregulatory effects of 
MSC are associated with the expansion of Foxp3+ regula-
tory T cells (Tregs) [7–9, 12] and in some cases to gener-
ate a state of Foxp3+ Tregs-dependent tolerance [7, 8, 12, 
15]. All of these studies elegantly show the importance of 
Foxp3+ Tregs in MSC induced tolerance using Foxp3+ 
Tregs depletion or adoptive transfer of Foxp3+ Tregs 
studies [7, 8, 12, 15].
Tregs are a CD4+ T cell population essential for main-
taining self-tolerance and immune homeostasis [17, 
18]. The role for Foxp3+ Tregs in allograft tolerance has 
received strong support from observations, including 
enhanced graft survival by adoptive transfer of Tregs 
populations [19, 20], the presence of small numbers of 
Tregs within the graft [21, 22] and peripheral induction 
of Foxp3+ Tregs following a tolerogenic protocol [23, 24]. 
A recent study provided definite proof that Foxp3+ Tregs 
are required not only to induce, but also to maintain the 
tolerant state [25]. Therefore, therapeutic strategies to 
induce and expand Foxp3+ Tregs in vivo may provide an 
attractive approach to guide the immune reconstitution 
towards tolerance.
The transcription factor forkhead box P3 (Foxp3), 
which encodes a forkhead/winged helix transcription 
factor known as scurfin, is a known master regulatory 
gene for the development and function of CD4+CD25+ 
Tregs that plays a vital role in both natural and induced 
Tregs differentiation from noncommitted precursors [18, 
26]. Previous studies have shown that Foxp3 is expressed 
specifically by Foxp3+ Tregs in the thymus and periphery 
of normal mice and humans, and its expression cannot be 
induced in naive T cells simply by activation [27, 28]. The 
retroviral transfer of Foxp3 converts naive T cells into a 
Tregs phenotype and function [27]. Moreover, recent 
studies have reported a large number of key target genes 
which were regulated directly by Foxp3 during T stimu-
lation, such as CD25, programmed cell death-1(PD-1)/
programmed death ligand 1(PD-L1), CD28 and neuropi-
lin-1 (Nrp-1), these target genes are the key modulators 
of immunosuppression [29, 30]. Based on these data, 
we utilized the characteristics of Foxp3 and MSC, then 
overexpressed Foxp3 in MSC through lentivirus carrying 
human Foxp3. We hypothesized that overexpression of 
Foxp3 in MSC could improve immunosuppressive capac-
ity of MSC and induce donor-specific allograft tolerance 
in rat’s liver allograft model.
Methods
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health). The 
protocol was approved by the Animal Ethics Commit-
tee of Central South University. All surgeries were per-
formed under sodium pentobarbital anesthesia, and all 
efforts were made to minimize animal suffering.
Isolation, culture, and characterization of MSC
Isolation and primary culture of MSC were performed 
according to previously reported method [31]. Isolated 
MSC were routinely characterized inhouse by flow 
cytometry for their cell surface markers, and differentia-
tion of MSC into adipocytes, chondrocytes and osteo-
blasts in  vitro was performed as previously described 
[32]. Passage 6–8 MSC were used for all experiments 
described. LEW MSC derived from the bone marrow 
were positive for MHC class I (RT1Al), Thy1 (CD90) and 
CD73, showed a weak expression of CD80 but lacked 
the expression of MHC class II, CD4, CD25, CD45, and 
CD49b as shown by flow cytometry. The resultant MSC 
had a spindle-shaped fibroblastic morphology and main-
tained their multilineage differentiation potential by 
maintaining their ability to differentiate into osterogenic, 
chondrogenic and adipogenic lineages when cultured in 
various specific differentiation media.
Cell preparation
Splenocyte (SC) suspensions were obtained by passing the 
mouse spleen through a 70-μm cell stainless steel strainer, 
and erythrocytes were depleted by hypotonic lysis. T cell-
depleted SC (act as APC) were enriched from pooled 
spleens by positive selection via magnetic-activated cell 
sorting (MACS) using a Pan T Cell Isolation Kit (Miltenyi 
Biotec). CD4+ T cells were enriched from the same pool by 
negative selection via MACS using a CD4+ T Cell Isolation 
Kit (Miltenyi Biotec). CD4+CD25− T cells were sorted by 
antibody cell sorting on an FACS Vantage SE with a FACS 
Diva Cell Sorter (BD Bioscience) to >99 % purity.
Antibodies and FACS analysis
The following monoclonal antibodies (mAbs) used: anti-
rat-Nrp-PE, anti-mouse-PD-L1-PE (eBioscience, San 
Diego, CA), anti-mouse/rat CD28-PE (Santa Cruz, CA), 
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anti-rat CD4-FITC, anti-rat CD25-PE, anti-rat Foxp3-
PE-cyanine 5 (eBioscience, San Diego, CA, USA). After 
membrane and intracellular staining, cells were analyzed 
on FACS CantoII using the BD FACSDiva v8.0 software.
Production of lentivirus
Lentivector (FUGW) and packaging (psPAX2) and 
envelope plasmids (pMD2.G) were obtained from 
Addgene. The cDNA encoding full-length human Foxp3 
(NM_014009.3) was amplified by RT-PCR from the 
cDNA of adult peripheral cells using specific primers, 
and digested with restriction enzymes subcloned to len-
tiviral vector backbone plasmid FUGW. To produce the 
recombinant lentivirus carrying Foxp3 (Foxp3) and con-
trol GFP (FUGW), the recombinant plasmid and vector 
were co-transfected with packaging and enveloping plas-
mids into 293FT cells by calcium phosphate transfection. 
The culture supernatant containing the virus was col-
lected and centrifuged at 15,000 rpm/min for 10 min to 
remove debris, and then transferred into a 36-mL ultra-
centrifuge tube for ultracentrifugation at 25,000 rpm/min 
for 3 h. The pellet containing lentivirus was resuspended. 
MSC were infected with the appropriate lentivirus where 
gene transfer efficiency reached at least 80 %.
Animals and experimental groups
LEW (MHC haplotype: RT11),ACI (MHC haplotype: 
RT1a) and BN (MHC haplotype: RT1n) rats weighing 
approximately 250 g were obtained from the Model Ani-
mal Research Center of Central South University, Chang-
sha, China. LEW or BN rats were used as liver transplant 
donors and ACI rats served as recipients. A rat non-arte-
rialized orthotopic liver transplantation model was per-
formed according to the techniques previously described 
by Kamada and Calne [33]. Injections of 2 ×  106 MSC, 
FUGW-MSC or Foxp3-MSC into the portal vein were 
carried out immediately after liver transplantation. ACI 
recipients were randomly assigned to 7 groups (Table 1): 
group 1, untreated group; group 2, treated with MSC; 
group 3, treated with Foxp3-MSC; group 4, treated 
with FUGW-MSC; group 5, treated with Foxp3-MSC 
(2 × 106) plus 15.0 mg/kg of rat anti-mouse CD25 mAb 
on days −2, 0, 2 after liver transplantation, intraperitoni-
ally (IP) and group 6 treated with Foxp3-MSC (2 × 106) 
plus rat control IgG; group 7, treated with 2 × 106 third 
party BN Foxp3-MSC and group 8, treated with 2 × 106 
recipient-derived ACI Foxp3-MSC.
Flow cytometry analysis
Cells were analyzed on a flow cytometer (BD Bioscience) 
according to a previously reported method [34]. For 
intracellular staining, cells were fixed and permeabilized 
with Cytofix/Cytoperm (BD PharMingen). The following 
mAbs were included: anti-rat CD25-PE, anti-rat CD4-
FITC, and anti-rat Foxp3-PE-cyanine 5 (eBioscience, San 
Diego, CA, USA). As to the Foxp3 antibody, an isotype-
matched control was used to determine the background. 
Tregs were identified as CD4+CD25+Foxp3+ triple-posi-
tive cells and were expressed as percentages in SC.
MLR and proliferation studies
MLR and proliferation studies were performed as previ-
ously described [7]. CD4+ T cells were used as respond-
ers (0.5  ×  106 cells) in the MLR. We used 4000-rad 
irradiated SC (0.5 × 106 cells) as stimulators. Cocultures 
also contained MSC from Lewis rats at ratios of 1:1 and 
1:100 in RPMI medium (Gibco Invitrogen, Karlsruhe, 
Germany) supplemented with 10 % FBS with 800 U/mL 
rat interleukin-2 (IL-2; BD Bioscience, Bedford, MA, 
USA). Transwell inserts were used in some wells (0.4-μm 
pore size; BDFalcon, San Jose, CA, USA). CD4+ T cells 
were cultured in the well beneath the insert. Cell prolif-
eration was determined by pulsing the cells with [3H]
thymidine during the last 14–16 h of culture and measur-
ing the radioactivity incorporated by liquid scintillation 
counting. Proliferative response was expressed as △cpm.
Antigen‑specific tolerance
Long-term ACI liver allograft recipients received full-
thickness skin grafts (1 ×  1  cm2) from LEW donor and 
BN rat strains on postoperative day (POD) 100 and were 
monitored daily (n  =  3). Rejection was defined as scar 
formation or epidermis sloughing or both.
Histology and liver function post‑orthotopic liver 
transplantation
Samples of liver tissue for histopathology were fixed 
by immersion in 4  % buffered formalin, embedded in 
Table 1 Experimental groups and  liver allograft survival 
in ACI recipients
* p < 0.05 vs untreated group; † p < 0.05 vs MSC group; †† p < 0.05 vs Foxp3-MSC 
group
Group n Injected cells Graft survival (days) MST 
(days)
1 6 No 11, 13 × 2, 14, 15, 16 13.5
2 8 Lewis MSC 16, 18, 20, 21 × 3, 24, 26 21.0*
3 8 Lewis Foxp3-MSC 63, >100 × 7 100*,†
4 6 Lewis FUGW-MSC 18 × 2, 20 × 2, 21, 23 20.0*
5 6 Lewis Foxp3-
MSC + α-CD25
12, 14 × 3, 16, 18 14.0
6 6 Lewis Foxp3- 
MSC + IgG
>100 × 6 100*,†
7 6 BN Foxp3-MSC 17, 19, 25, 26, 30, 35 25.5*
8 6 ACI Foxp3-MSC 31, 35, 41, 73, >100 × 2 57.0*,†,††
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paraffin, sectioned, and stained with hematoxylin-eosin. 
The histological findings of hematoxylin-eosin staining 
were graded according to the Banff scheme and rejection 
activity index (RAI) was calculated from the three indi-
vidual scores [35, 36]. For the evaluation of the engraft-
ment of GFP-MSC in the liver, tissues from GFP-labeled, 
MSC infused Lewis donor were rapidly frozen, sectioned 
on a cryostat (6  μm), fixed with acetone, and analyzed 
directly by fluorescence microscopy. For each tissue, 
three nonconsecutive sections were analyzed and GFP+ 
cells in each section were counted. Immunohistochem-
istry (IHC) was performed with anti-rat Foxp3 mAbs 
(1:100) according to the procedures described in the Bio-
Legend protocol. The levels of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST) and total biliru-
bin (TBIL) were measured with an autobiochemical ana-
lyzer (CX7; Beckman Coulter, Inc., Brea, CA, USA).
CD25+ cell depletion
CD25+ cells Deplation in  vivo was performed as previ-
ously described [12]. Briefly, mice received 15  mg/kg of 
rat anti-mouse CD25 mAb (clone PC-61, BioXcell) on 
days −2, 0, 2 after transplantation, CD25+ cell deple-
tion was confirmed on POD7 by staining splenocytes. 
Rat IgG1 injections at the same time point to reciprocal 
recipients served as isotype-matched controls.
Statistics
Allograft survival among experimental groups was com-
pared using log-rank (Mantel-Cox) testing. Statistical 
analysis for multiplicity was conducted using a one-way 
ANOVA or the Student t-test. Statistical Package for the 
Social Sciences for Windows (Version 14.0; SPSS Inc.) 
software was used for all statistical analyses, and p < 0.05 
was considered statistically significant.
Results
Successful gene transfer of foxp3 in MSC and Foxp3‑MSC 
engraftment in liver allograft
To confirm the successful gene transfer of Foxp3 in MSC 
through the lentivirus, the transduction efficiency and 
expression of Foxp3 were examined in Foxp3-engineered 
MSC cell lysates. MSC were efficiently transduced with 
>95  % GFP-positive cells (Fig.  1a). Western blot analy-
ses of cell lysis confirmed the production of Foxp3-GFP 
fusion protein in Foxp3 engineered MSC compared with 
MSC transfected with an empty vector 96 h after infec-
tion (Fig. 1b).
We next evaluated Foxp3-MSC engraftment in liver 
grafts by fluorescence microscopy. As demonstrated in 
Fig. 1c, we detected substantial numbers of GFP-Foxp3-
MSC (approximately 10–20 cells per section) liver graft 
of the recipients on POD7 after intraportal injection of 
allogeneic GFP-Foxp3-MSC. These finding suggests that 
Foxp3-MSC successful locates in the liver allograft.
Foxp3 transduction improved the immunosuppressive 
capacity of MSC and Foxp3‑MSC mediated 
immunomodulation involves cell–cell contact mechanisms
To evaluate the immunogenicity of MSC and Foxp3-
MSC, as shown in Fig. 2a, MSC and Foxp3-MSC was sig-
nificantly lower than the proliferation induced by mature 
splenocytes from LEW rats (Fig. 2a). Actually, ACI CD4+ 
T cell proliferation against LEW MSC or Foxp3-MSC 
was negligible.
To investigate the effects of Foxp3-engineered MSC on 
immunosuppressive activity, MLR and proliferation stud-
ies were performed. LEW MSC or Foxp3-MSC (MSC/
Foxp3-MSC: CD4+ T cells  =  1:10) significantly low-
ered the proliferative response of allogeneic ACI CD4+ 
T cells elicited by SC from the same MSC donor strain 
compared with PBS control group (Fig.  2a). LEW MSC 
or Foxp3-MSC at the same concentration also signifi-
cantly reduced the proliferation of allogeneic ACI CD4+ 
T cells to third-party SC from BN rat (Fig. 2a). Further-
more, Foxp3-MSC treatment was significantly lower than 
the proliferation of allogeneic ACI CD4+ T cells induced 
by SC from the same donor strain or third-party BN rat 
compared with MSC (Fig. 2a). To further test the effects 
of Foxp3-engineered MSC on immunosuppressive activ-
ity. ACI CD4+ T cells were cultured in MLR with allo-
geneic LEW SC in the presence of graded doses of LEW 
MSC or Foxp3-MSC. Both MSC and Foxp3-MSC were 
able to suppress the proliferation of allogeneic CD4+ T 
cells to alloantigens in a dose-dependent manner and 
Foxp3-MSC showed higher immunosuppressive power 
when compared with MSC (Fig.  2b). Therefore, both 
Foxp3-MSC and MSC are not immunogenic and donor 
specific, Foxp3-MSC share the similar immunologi-
cal properties with MSC and Foxp3 transduction sig-
nificantly improved the immunosuppressive capacity of 
MSC.
MSC-mediated immunomodulation involves both cell 
contact–dependent and cell contact–independent mech-
anisms mediated through the release of soluble factors. 
To determine the role of cell contact, trans-well experi-
ments were performed, in which direct contact between 
T cells and allogeneic Foxp3-MSC was prevented, Fig. 2a 
shows that when cell–cell contact is prevented, similar to 
MSC, the suppression effect of Foxp3-MSC on the pro-
liferation of ACI CD4+ T cells is significantly alleviated 
(p < 0.05 vs Foxp3-MSC). Therefore, the cell–cell contact 
is required to immunosuppresion activity of Foxp3-MSC.
We further investigate the phenotype of MSC altered 
by Foxp3 transduction. Foxp3-MSC and FUGW-MSC 
were isolated using a FACS and CD25, CD28, Nrp-1, 
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Fig. 1 Successful gene transfer of Foxp3 in MSC and Foxp3-MSC engraftment in liver allograft. a MSC were infected with control lentivirus (FUGW, 
Green) and GFP-Foxp3 lentivirus (Foxp3, Green), Nucleus were stained by DAPI (Blue). MSC were efficiently transduced with >95 % GFP-positive cells. 
b The expression of Foxp3 was detected by western blot in Foxp3-MSC and FUGW-MSC lysis at 96 h after infection. The production of Foxp3-GFP 
fusion protein was confirmed in Foxp3-MSC lysis compared with FUGW-MSC lysis. c Liver allograft sections were analyzed by fluorescence micros-
copy for the presence of GFP-Foxp3-MSC, substantial numbers of GFP-Foxp3-MSC liver graft were observed in liver allograft (upper panel, original 
magnification ×400; lower panel, original magnification ×100)
and PD-L1 regulated by transcription factors Foxp3 [30, 
37] were detected by FCM. MSC overexpressing Foxp3 
increased the expression of cell surface molecule Nrp-1 
and costimulatory molecule PD-L1 compared with 
FUGW-MSC (Fig.  2c); however, no difference between 
the two groups in the expression of cell surface mol-
ecule CD25 and costimulatory molecule CD28 was 
found (Fig. 2c). To study the role of the Nrp-1 and PD-L1 
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in mediating suppression of CD4+ T cell proliferation 
by LEW Foxp3-MSC, blocking experiments were per-
formed using 10 μg/ml of neutralizing antibodies against 
PD-L1 or Nrp-1. Foxp3-MSC treated with anti-PD-L1 
significantly increased the proliferation of allogeneic 
ACI CD4+ T cells elicited by SCs from LEW compared 
with Foxp3-MSC with IgG, while the presence of 10 μg/
ml of anti-PD-L1 antibody did not produce significant 
effect on the FUGW-MSC mediated inhibition of cell 
proliferation (Fig. 2d). Thus, the increased expression of 
PD-L1 in Foxp3-engineered MSC may be associated with 
its immunosuppressive capacity. On the other hand, the 
blockade of Nrp-1 did not produce significant effect on 
the FUGW-MSC or Foxp3-MSC mediated inhibition of 
CD4+ T cells proliferation (Fig. 2e).
Foxp3 transduction induced the expansion of Foxp3+ Tregs 
in vitro
To determine whether or not the immunoregulatory 
actions of Foxp3-MSC were associated with the expan-
sion of Tregs, CD4+ T cells were cocultured with MSC, 
Foxp3-MSC, or FUGW-MSC for 7d in the presence of 
APC and anti-CD3 mAb, and their FCM results were 
analyzed. Figure  2f, g shows that the MSC markedly 
increased the percentage of CD4+CD25+Foxp3+ T-cell 
population after 7 days of cocultures with CD4+ T cells, 
Furthermore, the percentage of CD4+CD25+Foxp3+ 
Tregs in the Foxp3-MSC group was significant higher 
than that in the MSC group.
Foxp3‑MSC monotherapy achieves donor‑specific liver 
allograft tolerance
To elucidate the tolerogenic effect of Foxp3-MSC on 
liver transplantation, MSC、Foxp3-MSC and FUGW-
MSC from donor Lewis rat were injected into ACI 
recipients immediately after receiving a orthotopic 
Lewis liver graft. Untreated allografts were rejected 
with a median survival time (MST) of 13.5 days (Table 1; 
Fig. 3a) and MSC or FUGW-MSC treated recipients sig-
nificantly prolong graft survival with a MST of 21.0 and 
20.0  days respectively (Table  1; Fig.  3a). Importantly, 
donor-derived Foxp3-MSC treated recipients achieved 
indefinite graft survival (>100  days) with almost nor-
mal histology (Fig. 3a, c). In contrast, third party Foxp3-
MSC did not influence graft survival as compared to 
animals receiving donor-derived MSC (Table  1, group 
7, p  =  0.16, compared to group 2), whereas two out 
of six animals treated with recipient-derived Foxp3-
MSC accepted their grafts long-term (Table  1, group 
8, p<0.05, compared to group 2 and group 3). Hence, 
donor-derived Foxp3-MSC is most effective for toler-
ance induction.
Next, we examined the pathology and function of liver 
allografts. As shown in Fig. 3c, severe acute rejection was 
present in the untreated groups at day 7 postoperatively; 
moderate acute rejection with milder vacuolation of 
hepatic cells and less inflammatory cell infiltration were 
observed in rat treated with MSC or FUGW-MSC com-
pared to untreated group. However, Foxp3-MSC treat-
ment achieved almost normal histology on POD 7. At the 
same time, RAI score of Foxp3-MSC group was markly 
lower than that in untreated, MSC or FUGW-MSC con-
trol group (Fig.  3d). The serum concentrations of liver 
enzymes (ALT and AST) and TBIL were significantly 
decreased after Foxp3-MSC treatment compared with 
those after treatment with untreated, MSC or negative 
control lentivirus (Fig. 3e, f ).
To study whether the long-term graft acceptance was 
associated with donor-specific tolerance, Full-thickness 
skin transplantation was also performed, skin grafts 
from either LEW donor or BN third-party rat were trans-
planted to long-term surviving ACI recipients on POD 
100, BN third-party skin grafts were rejected within 
14  days, while LEW donor skin grafts were survived 
over 100 days (data not shown). A histological examina-
tion of skin grafts were completed on POD 7 after skin 
transplantation, intense infiltration of inflammatory cells 
was observed in the epidermis and dermis of the BN 
third-party skin grafts (Fig.  3g) but not in LEW donor 
skin grafts, indicating that donor-specific tolerance was 
achieved in LEW Foxp3-MSC treated liver allograft 
recipients.
(See figure on previous page.) 
Fig. 2 Foxp3 transduction improved the immunosuppressive activity of MSC and induced the expansion of Foxp3+ Tregs. a The immunogenicity 
of Foxp3-MSC and effect of Foxp3-MSC on T cell proliferative response in vitro. Results are mean ± SE of three independent experiments. *p < 0.05 
vs PBS; #p < 0.05 vs MSC; &p < 0.05 vs Foxp3-MSC. b Foxp3 transduction significantly improved the immunosuppressive activity of MSC. Results are 
mean ± SE of three independent experiments. *p < 0.05 vs MSC. c The expression of cell surface molecule in MSCs altered by Foxp3 transduction. 
Isotype FUGW-MSC are represented by open histograms and Foxp3-MSC by closed histograms. d, e Blocking experiments with neutralizing mAb of 
Nrp-1 and PD-L1 on CD4+ T cell proliferative response. Results are representative of three independent experiments. *p < 0.05 vs PBS; #p < 0.05 vs 
Foxp3-MSC + IgG. f Frequency of CD4+CD25+Foxp3+ T cells. Results are representative of five independent experiments. *p < 0.05 vs PBS; #p < 0.05 
vs MSC. g Representative dot plots of CD25 and Foxp3 staining of CD4+-gated cells. Percentages of CD4+CD25+Foxp3+ T cells are indicated in the 
top right corners of each dot plot
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Foxp3‑MSC increase CD4+CD25+Foxp3+ Tregs 
frequencies and generate a state of CD4+CD25+Foxp3+ 
Tregs‑dependent tolerance
Because CD4+CD25+Foxp3+ Tregs proportions had pre-
viously been confirmed to increase on co-culturing naïve 
T cells with Foxp3-MSC in  vitro (Fig.  2f, g), we exam-
ined whether CD+CD25+Foxp3+ T cells contributed to 
liver allograft acceptance in Foxp3-MSC treated allograft 
recipients. Our data showed that tolerant recipients had a 
significant increase in splenic CD4+CD25+Foxp3+ Tregs 
frequency compared with other control groups (Fig.  4a, 
b). For confirmation, immunohistochemical analysis of 
Foxp3+ cells was also performed in liver allograft tissues 
to document Tregs recruitment at the graft site. Signifi-
cant numbers of intragraft positive staining Foxp3 cells 
were found in Foxp3-MSC treated recipients compared 
with untreated, MSC or FUGW-MSC treated recipients 
on POD 7 (Fig.  4c, d). These results indicate that graft 
tolerance induced by Foxp3-MSC is associated with the 
accumulation of Foxp3+ Tregs in the graft.
To understand the immunological role of 
CD4+CD25+Foxp3+ Tregs behind Foxp3-MSC mediated 
long-term graft acceptance, CD25+ T cells were depleted 
by in vivo administration of an α-CD25 monoclonal anti-
body (mAb) on days −2, 0, 2 after transplantation, and 
CD4+CD25+Foxp3+ T cells frequencies were confirmed 
less than 0.9  % of the mononuclear cell population on 
POD7. As shown in Table  1 and Fig.  3b, although hav-
ing received Foxp3-MSC treatment, liver grafts were 
rejected in 20 days after CD25+ T cells depletion. In con-
trast, Foxp3-MSC recipients received isotype control IgG 
maintained long-term liver graft survival. These data fur-
ther indicating a critical role for Foxp3+ Tregs in Foxp3-
MSC inducing tolerance.
Discussion
MSC have recently emerged as promising candidates for 
cell-based immunosuppression/tolerance and can be eas-
ily obtained and propagated in culture [7–9]. However, 
treatment with MSC alone only prolonged allograft sur-
vival but could not induce allograft tolerance in rodent 
transplantation models [8, 9, 11, 13, 38, 39]. MSC also 
only be applied as a complement to standard immuno-
suppressive therapy in a clinical setting [14, 15]. Previous 
studies have been performed to show that gene modifi-
cation of MSC, including the incorporation of exogenous 
genes such as IL-10 [40], hepatocyte growth factor [41], 
IL-7 [42] successfully improve MSC therapeutic ability. In 
the present study, we intended to enhance the tolerogenic 
effect of MSC by overexpressing gene Foxp3. Our results 
show that Foxp3-MSC is not donor specific/immuno-
genic, Foxp3 transduction significantly improve the 
immunosuppressive capacity of MSC, Foxp3-MSC sup-
pressive effect on the proliferation of CD4+ T cells is con-
tact dependent and associated with PD-L1 upregulation. 
More importantly, Foxp3-MSC monotherapy achieves 
donor-specific liver allograft tolerance, the tolerogenic 
potential of Foxp3-MSC is associated with the expansion 
of CD4+CD25+Foxp3+ Tregs.
Foxp3 is essential for specifying the Foxp3+ Treg cell 
lineage during development, and continued expression 
of Foxp3 in mature Treg cells is necessary for suppres-
sive function [43]. Deletion of Foxp3 in fully differentiated 
mature Treg cells results in the deregulation of its target 
genes and the loss of suppression function [44]. Previous 
studies have identified Foxp3 target genes and reported 
a large number of Foxp3-bound genes that are up- or 
down-regulated in Foxp3+ T cells, suggesting that Foxp3 
acts as both a transcriptional activator and a repressor. 
Furthermore, Foxp3 probably sets up a transcription fac-
tor network controlling the overall functional program of 
Tregs [29, 30]. The present study utilized a lentivirus vec-
tor to modify MSC to overexpress the therapeutic gene 
Foxp3, the findings suggested that the immunosuppres-
sive effect of rat Foxp3-MSC was dose dependent and 
not donor specific/immunogenic in vitro. Indeed, Foxp3-
MSC/MSC inhibited the proliferative response of both 
autologous and allogeneic CD4+ T cells to either donor or 
third-party alloantigens in MLR, which is consistent with 
most published studies [7–9, 11–13]. Moreover, Foxp3 
transduction significantly improved the immunosup-
pressive capacity of MSC, Further analyses indicated that 
Foxp3-MSC mediated immunomodulation involved cell–
cell contact mechanisms. Using neutralizing antibodies 
specific for PD-L1, we showed that the mechanisms by 
which Foxp3-MSC mediated enhanced immunosuppres-
sive capacity was associated with costimulatory molecule 
PD-L1 of MSC altered by Foxp3 transduction.
(See figure on previous page.) 
Fig. 3 Foxp3-MSC monotherapy achieves donor-specific liver allograft tolerance. a Kaplan–Meier survival curves for untreated, donor-derived MSC, 
FUGW-MSC and Foxp3-MSC, recipient-derived Foxp3-MSC and third party Foxp3-MSC groups. b Kaplan–Meier survival curves for the Foxp3-MSC, 
Foxp3-MSC+IgG and Foxp3-MSC+α-CD25 groups. c Histology of liver allografts in ACI recipients on POD 7 (H&E, original magnification ×100). d RAI 
scores according to the Banff scheme. Results are mean ± SE of five independent experiments. *p < 0.05 vs untreated; #p < 0.05 vs MSC. e, f Changes 
in the serum ALT, AST and TBIL concentrations in all 4 groups 7 days after LT. Results are mean ± SE of three independent experiments. *p < 0.05 vs 
untreated; #p < 0.05 vs MSC. g Representative skin biopsy samples were obtained on day 7 and 100 after skin transplantation (H&E, original magnifi-
cation ×100)
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Programmed death-1 (PD-1) is a molecule expressed 
on various cell types, including a subset of thymocytes 
and activated T and B cells that plays an important role 
in the negative regulation of immune responses and the 
maintenance of peripheral tolerance [45]. PD-1 ligand, 
PD-L1, broadly expressed in different tissues, has been 
shown to be further induced by exposure to interferon 
(IFN)-γ on several tumour cell lines and MSC [45, 46]. 
The exact immune functions of PD-L1 are not fully under-
stood. With respect to immunosuppression mediated 
by MSC, our findings are consistent with previous study 
that murine MSC inhibit lymphocyte proliferation by 
activation of the PD-L1-mediated signaling pathway [47]. 
The study showed that MSC inhibited the activation and 
proliferation of murine lymphocytes via engagement of the 
inhibitory molecule PD-L1 to its cognate receptor on tar-
get immune cells, and MSC-mediated inhibition could be 
blocked by anti-PD-L1 antibody [47, 48]. Recently, it has 
been shown that IFN-γ acts directly on MSC leading to an 
up-regulation of PD-L1, and PD-L1 knockdown abolished 
MSC suppressive properties [49]. In vivo, the combina-
tion therapy of MSC with PD-L1 expression and rapamy-
cin induced immune tolerance to cardiac allografts, while 
the blockade of PD-L1 on MSC with monoclonal antibody 
abrogated the combination therapy-induced immune 
tolerance [50]. The PD-1/PD-L1 pathway is essential for 
costimulatory blockade-induced allograft tolerance, which 
reflects the roles of the pathway in controlling T effector 
Fig. 4 Frequency of Tregs generated in ACI recipients. a Representative dot plots of splenic Tregs. Percentages of CD4+CD25+Foxp3+ T cells are 
indicated in the top right corners of each dot plot. b Graphic results of frequency of splenic CD4+CD25+Foxp3+ T cells. Results are representative of 
five independent experiments. *p < 0.05 vs untreated; #p < 0.05 vs MSC. c Graphical representation of numbers of Foxp3+ T cells (cells/mm2) within 
the liver allografts. The results are representative of six separate experiments. *p < 0.05 vs untreated; #p < 0.05 vs MSC. d Representative immunohis-
tochemistry staining of intragraft Foxp3+ T cells. (IHC, original magnification ×100)
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cell proliferation, as well as the induction of T-cell anergy 
[51]. However, whereas English and collaborators reported 
that PD-1 pathway was not essential for MSC mediated 
immunosuppression [52]. The reasons for these differ-
ences are most likely due to the use of different stem cell 
populations and immune cells. Indeed, the authors used 
not only MSC with different phenotypes but also hetero-
geneous population of immune cells such as splenocytes 
or lymphocytes. Taken together our results demonstrated 
the cell-to-cell contact depend mechanism of Foxp3-MSC 
immunosuppression on CD4+ T cells is most likely to 
involve the up-regulation of PD-L1.
In order to determine how Foxp3-MSC modulated 
Tregs in our study, we cocultured Foxp3-MSC/MSC 
with CD4+ T cells in  vitro (MLR) to mimic some of 
the conditions in vivo. Co-culture of CD4+ T cells with 
Foxp3-MSC results in a shift towards a Tregs pheno-
type compared with MSC group. MSC are known to 
express cell adhesion molecules [53] and several authors 
have confirmed that direct interaction with target cells 
is a requirement for their overall immunosuppressive 
effect [53, 54]. However, there is currently a notable 
lack of information on the importance of, and mecha-
nisms underlying, the induction of Tregs by MSC via 
contact-dependent mechanisms [55]. Studies have also 
shown other factors may be able to substitute for cell-
to-cell contact in some situations, as cell-to-cell contact 
was essential when MSC were co-cultured with purified 
CD4+ T cells, but this direct interaction was not essential 
when MSC were exposed to an un-fractionated mononu-
clear cell population [56]. These findings are consistent 
with a cell contact-dependent mechanism as suggested 
by the phenotype of MSC altered by Foxp3 transduction 
experiments in which Foxp3 transduction led to an up-
regulation of PD-L1 on MSC. In the present study, the 
importance of Tregs in induction of transplant tolerance 
was also supported by high frequencies of Foxp3+ Tregs 
in the spleens and liver allografts of tolerant recipients. 
Antibody-mediated depletion of CD25+ cells abrogated 
liver allograft tolerance despite administration of Foxp3-
MSC, further indicating a critical role for Tregs. These 
results suggested that the induction and maintenance 
phases of tolerance after donor-derived Foxp3-MSC infu-
sion in rats are associated with the emergence of func-
tional Tregs.
In this study, Foxp3-MSC/MSC were well detected in 
the recipient liver allografts after portal vein injection, 
suggests that Foxp3-MSC/MSC migration and/or pro-
liferation is influenced by tissue injury and/or inflamma-
tory signals. These results are also in line with previous 
studies indicating that the liver is an immune privileged 
organ for tolerance induction by donor cell infusion [7, 
9, 15]. Foxp3-MSC treatment significantly lowered the 
proliferation of allogeneic ACI CD4+ T cells to SC from 
the same donor strain or third-party BN rat. However, 
in our model third party MSC did not induce graft toler-
ance, whereas two out of six animals treated with recip-
ient-derived Foxp3-MSC accepted their grafts long-term 
(Table 1; Fig. 3b). These findings are consistent with previ-
ous studies [7, 32] and implicate that MSC cannot be used 
from arbitrary donors in a clinical transplantation setting. 
Understanding the mechanism behind MSC mediated 
tolerance most likely helps to augment the efficiency of 
recipient-derived MSC, which makes this strategy clini-
cally applicable to cadaveric organ transplantation.
Conclusions
In this study, Foxp3 transduction significantly improved 
the immunosuppressive activity of MSC, although 
immunomodulatory mechanisms of Foxp3-MSC remain 
unclear, Foxp3-MSC suppressive effect on the prolifera-
tion of CD4+ T cells is contact dependent and associated 
with PD-L1 upregulation. Foxp3 transduction induced 
the expansion of Foxp3+ Tregs and they played an impor-
tant role in Foxp3-MSC induced liver allograft tolerance. 
Foxp3-engineered MSC therapy seems to be a promising 
and attractive cell therapy approach for inducing immu-
nosuppression or transplant tolerance.
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